Oncotarget

Research Papers:

Targeted photodynamic therapy treatment of in vitro A375 metastatic melanoma cells

Channay Naidoo, Cherie Ann Kruger and Heidi Abrahamse

PDF  |  Full Text  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:6079-6095. https://doi.org/10.18632/oncotarget.27221

Metrics: PDF 614 views  |   Full Text 794 views  |   ?  


Abstract

Channay Naidoo1, Cherie Ann Kruger1 and Heidi Abrahamse1

1 Laser Research Centre, University of Johannesburg, Johannesburg, South Africa

Correspondence to:

Cherie Ann Kruger,email: cherier@uj.ac.za

Keywords: metastatic melanoma; nano active targeting; zinc phthalocyanine tetra-sulphonic acid; photodynamic therapy

Received: July 17, 2019     Accepted: August 17, 2019     Published: October 22, 2019

ABSTRACT

Metastatic Melanoma (MM) is a deadly form of skin cancer and many photodynamic therapy (PDT) studies have noted limitations in relation to effective photosensitizer (PS) drug uptake in tumors. The focus of this study was to develop a PS multicomponent nanoparticle drug conjugate carrier system which specifically targets MM cells via biomarkers to actively enhance PS delivery and so improve MM PDT. An antibody-metallated phthalocyanine-polyethylene glycol-gold nanoparticle drug conjugate, was successfully synthesized and characterized. PS active drug targeting PDT experiments at 673 nm were conducted within in vitro cultured MM. Results noted that this drug conjugate enhanced the PDT treatment of MM, through improved subcellular localization of the PS, as well as noted significantly improved cytotoxic and late apoptotic cellular death in cells. The results from this study demonstrate that through the bio-active antibody PS drug targeting of MM, the efficacy of PDT treatment for this cancer can be enhanced.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27221